Clinical trial · Observational
Detection of High Expression Levels of EMT-Transcription Factor mRNAs in Patients With Pancreatic Cancer and Their Diagnostic Potential
NCT04323917CI-TRIAL-00046520unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The present study is aimed at detecting and measuring mRNA levels of genes involved in epithelial to mesenchymal transition (EMT) in biological samples, i.e. in peripheral blood samples of pancreatic cancer (PC) patients and healthy controls, to determine the presence of disease, its progression and risk of recurrence.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Liquid biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cases
- description
- Subjects affected by Pancreatic carcinoma (PC) confirmed by tissue biopsy
- interventionNames
- Diagnostic Test: Liquid biopsy
- label
- Controls
- description
- Healthy Subject enrolled following colon cancer screening via colonoscopy
- interventionNames
- Diagnostic Test: Liquid biopsy
Primary outcomes (1)
- measure
- Assessments of diagnosis of PC by EMT-TF mRNA levels in blood
- timeFrame
- Analysis at day 0: at diagnosis or before surgery for PC patients; before colonoscopy in controls
- description
- To determine the stage, the remission or the progression of a pancreatic cancer in a pancreatic cancer affected subject not administered with an appropriate antitumor treatment (e.g., neo-adjuvant therapy) comprising the step of assaying a biological sample from said subject for the presence of a panel of mRNAs encoding for transcription factors involved in epithelial to mesenchymal transition.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Males or females over 18 years of age capable of providing informed consent. 2. Pancreatic carcinoma confirmed by tissue biopsy or colon mass, clinically consistent with cancer and eventually confirmed by pathology. 3. Subject were enrolled following colon cancer screening via colonoscopy Exclusion Criteria: 1. Patients under the age of 18 years or over the age of 80 years. 2. Patients with personal history of cancer, identification of large polyp or adenomatous pathology on previous or subsequent colonoscopy 3. Patient with history of abdominal surgery within the past four months 4. Patients unwilling to or unable to give informed consent. 5. Patients with acute inflammatory diseases or under any emergency condition. 6. Pregnant women.
References
Publications (1)
- BACKGROUNDCelesti G, Di Caro G, Bianchi P, Grizzi F, Basso G, Marchesi F, Doni A, Marra G, Roncalli M, Mantovani A, Malesci A, Laghi L. Presence of Twist1-positive neoplastic cells in the stroma of chromosome-unstable colorectal tumors. Gastroenterology. 2013 Sep;145(3):647-57.e15. doi: 10.1053/j.gastro.2013.05.011. Epub 2013 May 15. PMID 23684708